Bonnie S. Glisson mainly focuses on Internal medicine, Surgery, Chemotherapy, Radiation therapy and Oncology. His work on Internal medicine is being expanded to include thematically relevant topics such as Gastroenterology. His Chemotherapy research incorporates themes from Liver function, Squamous carcinoma and Epidermoid carcinoma.
His biological study spans a wide range of topics, including Salvage therapy and Laryngectomy. His work in Oncology addresses issues such as Clinical trial, which are connected to fields such as Toxicity and Salivary gland. His studies in Cisplatin integrate themes in fields like Cancer research, Urology, Tolerability, Fluorouracil and Larynx.
His primary scientific interests are in Internal medicine, Oncology, Chemotherapy, Lung cancer and Cancer research. In his study, Toxicity is inextricably linked to Gastroenterology, which falls within the broad field of Internal medicine. The concepts of his Oncology study are interwoven with issues in Head and neck squamous-cell carcinoma and Epidermal growth factor receptor.
Chemotherapy is the subject of his research, which falls under Surgery. His research in Surgery intersects with topics in Carcinoma and Epidermoid carcinoma. His Lung cancer research includes themes of Gemcitabine and Adenocarcinoma.
His scientific interests lie mostly in Internal medicine, Oncology, Cancer research, Lung cancer and Cancer. The Oncology study combines topics in areas such as Head and neck squamous-cell carcinoma, Radiation therapy and Chemotherapy, Phases of clinical research. His Radiation therapy study combines topics in areas such as Survival analysis, Performance status and Head and neck.
His work deals with themes such as Immune checkpoint, Blockade, Immunotherapy, Cell and Non small cell, which intersect with Cancer research. His Lung cancer study integrates concerns from other disciplines, such as Survival rate and Reverse phase protein lysate microarray. His research on Cancer frequently connects to adjacent areas such as Cohort.
His primary areas of study are Internal medicine, Oncology, Lung cancer, Cancer research and Cancer. His study in Induction chemotherapy, Phases of clinical research, Radiation therapy, Nivolumab and Chemotherapy is carried out as part of his Internal medicine studies. His research integrates issues of Regimen, Immune checkpoint inhibitors, PD-L1, Targeted therapy and Clinical endpoint in his study of Oncology.
His Lung cancer research integrates issues from Survival rate, Rovalpituzumab tesirine and Carcinoma. His study in Cancer research is interdisciplinary in nature, drawing from both Immune checkpoint, Immunotherapy, Gene expression, Allele frequency and DNA repair. His studies deal with areas such as Basal cell carcinoma, Eyelid Carcinoma and Surgery as well as Cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer
Arlene A. Forastiere;Helmuth Goepfert;Moshe Maor;Thomas F. Pajak.
The New England Journal of Medicine (2003)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski.
Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer
Arlene A. Forastiere;Qiang Zhang;Randal S Weber;Moshe H. Maor.
Journal of Clinical Oncology (2013)
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer
Stephen G. Swisher;Jack A. Roth;John Nemunaitis;David D. Lawrence.
Journal of the National Cancer Institute (1999)
Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225
Nancy Lee;Jonathan Harris;Adam S Garden;William Straube.
Journal of Clinical Oncology (2009)
Role of Topoisomerase II in Mediating Epipodophyllotoxin-induced DNA Cleavage
Warren Ross;Tom Rowe;Bonnie Glisson;Jack Yalowich.
Cancer Research (1984)
Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11.
Randal S. Weber;Brian A. Berkey;Arlene Forastiere;Jay Cooper.
Archives of Otolaryngology-head & Neck Surgery (2003)
Adenovirus-Mediated p53 Gene Transfer in Sequence With Cisplatin to Tumors of Patients With Non–Small-Cell Lung Cancer
J. Nemunaitis;S.G. Swisher;T. Timmons;D. Connors.
Journal of Clinical Oncology (2000)
Epidermal Growth Factor Receptor-targeted Therapy with C225 and Cisplatin in Patients with Head and Neck Cancer
Dong M. Shin;Nicholas J. Donato;Roman Perez-Soler;Hyung Ju C. Shin.
Clinical Cancer Research (2001)
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
F V Fossella;J S Lee;D M Shin;M Calayag.
Journal of Clinical Oncology (1995)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: